ClinicalTrials.gg
CompletedNCT03571789CAPTUREUpdated Feb 20, 2025

Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients

An interventional study of Vine™ in Atrial Fibrillation, sponsored by Javelin Medical. Completed at 4 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Javelin Medical · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Atrial Fibrillation with a site in Belgium — 34 open to participants now, 52 under way, 1 of them phase 3. Atrial Fibrillation · Belgium.

Enrollment
158th of 160
25 · median 296
Started
2017
with 14 others
No phase
102 of 205
22 open now
Registered
94th of 205
by date

Among the 205 studies in Atrial Fibrillation with a site in Belgium, this one is the 158th largest by enrollment of the 160 interventional ones that give a count, is one of 15 that started in 2017, is one of 102 with no phase, and was the 94th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

34 of the 205 studies in Atrial Fibrillation with a site in Belgium are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Atrial Fibrillation with a site in Belgium, or all of them as a file.
02

Study summary

Vine™ is a permanent carotid filter designed to provide protection against embolic stroke in people with atrial fibrillation. It is implanted bilaterally in the common carotid arteries from a thin needle under ultrasound guidance. The procedure is performed without general anesthesia and takes minutes. The safety, feasibility and tolerability of Vine™ will be evaluated. Patients who are eligible will receive Vine™ and will be followed-up for a year after device implantation.

Read the detailed description

CAPTURE is a prospective, single-arm, multicenter trial, designed to evaluate the safety, feasibility and tolerability of the Vine™ permanent carotid filter. The trial will enroll up to 30 patients, and will be conducted in up to five sites worldwide. All enrolled patients will be invited for non-invasive follow-up tests and clinical evaluations according to the study protocol.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • AF
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Atrial fibrillation (AF): documented persistent or permanent
  2. CHA2DS2-VASc score ≥ 4
  3. Age > 50
  4. Unsuitable for oral anticoagulation therapy (OAC), defined as for OAC, patient refusing OAC, or physician is reluctant to prescribe OAC
  5. Maximal (systolic) CCA diameter range: ≥ 5.3mm and ≤ 9.8mm
  6. CCA accessibility: up to 60mm from skin to CCA center, safe approach
  7. Patient is willing to provide
  8. Patient is willing to complete all scheduled follow-up

Exclusion criteria

Exclusion Criteria:

  1. Evidence of carotid stenosis > 30% [CCA, internal carotid artery (ICA), or external carotid artery (ECA)
  2. Evidence of any atherosclerotic disease in CCA above the clavicles
  3. Evidence of carotid dissection
  4. Pre-existing stent(s) in CCA
  5. or allergic to antiplatelet therapy, or any medication required during the study
  6. Recent stroke, , or myocardial infarction (MI) within two months prior to index procedure
  7. Female who is pregnant or who is planning to become pregnant during the course of the study
  8. of less than 1 year
  9. Active systemic infection
  10. Known sensitivity to nickel or titanium metals, or their alloys
  11. Known hereditary or acquired coagulation disorders
  12. Any planned surgical or endovascular procedure within 14 days prior to or 30 days after the index procedure
  13. A co-morbid disease or condition that could confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments
  14. Current use or a recent history of illicit drug(s) use or alcohol abuse (defined as regular or daily consumption of more than four alcoholic drinks per day)
  15. Active participation in another drug or device treatment study
  16. Any other condition that in the opinion of the investigator may adversely affect the safety of the subject or would limit the subject's ability to complete the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Vine™ implantation bilaterally in the common carotid arteries

    Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.

    Device: Vine™

Interventions

  • DeviceVine™

    The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils. The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters

06

What researchers measure

Primary outcomes

  1. Number of patients with no incidence of device and/or procedure related Major Adverse Events (MAEs)

    Major Adverse Events (MAEs) are defined as: * Death * Major and minor strokes * Major bleeding * Common carotid artery (CCA) stenosis \> 70% * Vine™ migration * CCA thrombus * Any complications in the CCA requiring endovascular treatment or surgery

    Time frame: 30 days from implantation procedure

  2. Number of patients with Procedure Success

    Procedure Success is defined as Proper Vine™ Position in each CCA Proper Vine™ Position is defined as: * Supporting coil in contact with artery walls * No migration * No fracture * No Vine™ coils or portions thereof visible outside the arterial lumen * No entangled or overlapping coils

    Time frame: 30 days from implantation procedure

Secondary outcomes

  1. Number of patients with no incidence of device and/or procedure related Major Adverse Events (MAEs)

    Death * Major and minor strokes * Major bleeding * Common carotid artery (CCA) stenosis \> 70% * Vine™ migration * CCA thrombus * Any complications in the CCA requiring endovascular treatment or surgery

    Time frame: within 3, 6, months,1, 2, 3, 4 and 5 years of implantation procedure

  2. Number of Successful Delivery and Deployment Attempts

    Successful Delivery and Deployment Attempts is defined as Proper Vine™ Position

    Time frame: within 4 hours of implantation procedure

  3. Number of patients with properly positioned Vine™ in each CCA

    Proper implant position

    Time frame: within 3, 6, months,1, 2, 3, 4 and 5 years of implantation procedure

07

Study locations

4 sites
  • OLV Ziekenhuis
    Aalst, Belgium
  • ZNA Stuivenberg
    Antwerp, Belgium
  • Na Homolce Hospital
    Prague, Czechia
  • Sint-Antonius ziekenhuis
    Nieuwegein, Netherlands
08

References and documents

Publications

  • Reddy VY, Neuzil P, de Potter T, van der Heyden J, Tromp SC, Rensing B, Jiresova E, Dujka L, Lekesova V. Permanent Percutaneous Carotid Artery Filter to Prevent Stroke in Atrial Fibrillation Patients: The CAPTURE Trial. J Am Coll Cardiol. 2019 Aug 20;74(7):829-839. doi: 10.1016/j.jacc.2019.04.035. Epub 2019 May 11. Erratum In: J Am Coll Cardiol. 2019 Aug 20;74(7):1013-1014. doi: 10.1016/j.jacc.2019.07.025. PubMed 31085320 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Dec 2018, 15 months.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 15 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2018
First posted
Jun 28, 2018
StartActual
Sep 12, 2017
Primary completionActual
Dec 13, 2018
CompletionActual
Nov 28, 2023
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03571789
Lead sponsor
Javelin Medical
Responsible party
Sponsor
First posted
Jun 28, 2018
Start date
Sep 12, 2017
Primary completion
Dec 13, 2018
Completion
Nov 28, 2023
Last update
Feb 20, 2025

Study contacts

Petr Neuzil, MD
principal investigator · Na Homolca Hospital
Jan Van der Heijden, MD
principal investigator · St. Antonius Hospital
Tom De Potter, MD
principal investigator · OLV Ziekenhuis
Stefan Verheye, MD
principal investigator · ZNA Stuivenberg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion